Characteristics of SARS-CoV-2 Reinfection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1144 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-12-15

Study Completion Date

2023-03-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

As the COVID-19 pandemic continues and the number of individuals with previous infection rises, numbers of SARS-CoV-2 reinfection are increasing. The second Omicron wave in Shanghai, China caused by BA.5-sublineages led to a large fraction of reinfections among BA.2 primary infections. To better understand the SARS-CoV-2 reinfection rate and clinical severity of reinfections, the investigators conducted a multi-centre cohort study. The investigators hope to provide valuable clinical evidences for reinfections and offer guidance for future policy making.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Epidemiological Study on Asymptomatic Infections and Mild Illness With Covid-19 in Shanghai

NCT05375786

COVID-19

UNKNOWN

A Retrospective Study in Patients With Mild to Moderate COVID-19

NCT05374772

COVID-19

UNKNOWN

Clinical, Virological, Serological and Immunological Characteristics During and Following COVID-19 Hospitalization

NCT05274373

COVID-19 Pneumonia COVID-19

UNKNOWN

A Follow-up Study of Asymptomatic Infections and Diagnosed Patients With Covid-19 in Shanghai

NCT05387304

COVID-19

RECRUITING

Survey of COVID-19 Infection

NCT05706064

COVID-19 Infections

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators used data from Huashan Hospital, Renji Hospital, and Shanghai Jing' an Central Hospital to collect information on SARS-CoV-2 primary infections with BA.2 during 1 March to 23 May 2022, and followed up for participants' reinfections with BA.5-lineages during 1 December 2022 to 14 January 2023. After matched 1:1 by age and gender with the reinfection cohort, data of primary infections with BA.5-sublineages were also collected. Reinfection cases were defined as having positive COVID-19 PCR or antigen test, at least 90 days after participants' first positive testing. Basic information, vaccination status, time interval between two infections, and clinical manifestations were collected.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Primary infections during March-May 2022

Hospitalized COVID-19 patients infected with BA·2 during 1 March to 23 May 2022 from Huashan Hospital, Renji Hospital, and Shanghai Jing' an Central Hospital.

No interventions assigned to this group

Primary infections during December 2022-January 2023

Primary infections with BA.5-sublineages during 1 December 2022 to 14 January 2023, matched 1:1 by age and sex with reinfections during the same period.

No interventions assigned to this group